false--12-31Q120210001237831YesDEYesP1YP1Y0.005P4Y00012378312020-09-3000012378312020-06-3000012378312020-03-1100012378312020-04-012020-06-3000012378312020-01-012021-03-310001237831us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-03-310001237831us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-01-012020-03-310001237831us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001237831us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001237831us-gaap:RetainedEarningsMember2021-03-310001237831us-gaap:AdditionalPaidInCapitalMember2021-03-310001237831us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001237831us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001237831us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001237831us-gaap:RetainedEarningsMember2020-12-310001237831us-gaap:AdditionalPaidInCapitalMember2020-12-310001237831us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001237831us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001237831us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001237831srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-03-310001237831us-gaap:RetainedEarningsMember2020-03-310001237831us-gaap:AdditionalPaidInCapitalMember2020-03-310001237831us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001237831srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-03-310001237831us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001237831us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001237831us-gaap:RetainedEarningsMember2019-12-310001237831us-gaap:AdditionalPaidInCapitalMember2019-12-310001237831us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001237831us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-03-310001237831us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-03-310001237831us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001237831us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001237831us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-03-310001237831us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-03-310001237831us-gaap:CommonClassBMemberus-gaap:CommonStockMember2019-12-310001237831us-gaap:CommonClassAMemberus-gaap:CommonStockMember2019-12-310001237831gmed:EquityIncentivePlan2012Memberus-gaap:CommonClassAMember2021-03-310001237831us-gaap:RestrictedStockUnitsRSUMember2021-03-310001237831us-gaap:RestrictedStockUnitsRSUMember2020-12-310001237831us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001237831us-gaap:NonUsMember2021-01-012021-03-310001237831gmed:SpineMember2021-01-012021-03-310001237831gmed:EmergingTechnologyMember2021-01-012021-03-310001237831country:US2021-01-012021-03-310001237831us-gaap:NonUsMember2020-01-012020-03-310001237831gmed:SpineMember2020-01-012020-03-310001237831gmed:EmergingTechnologyMember2020-01-012020-03-310001237831country:US2020-01-012020-03-310001237831srt:MinimumMemberus-gaap:EquipmentMember2021-01-012021-03-310001237831srt:MinimumMembersrt:OtherPropertyMember2021-01-012021-03-310001237831srt:MaximumMemberus-gaap:EquipmentMember2021-01-012021-03-310001237831srt:MaximumMembersrt:OtherPropertyMember2021-01-012021-03-310001237831us-gaap:BuildingAndBuildingImprovementsMember2021-01-012021-03-310001237831gmed:ModulesAndCasesMember2021-01-012021-03-310001237831gmed:InstrumentsMember2021-01-012021-03-310001237831us-gaap:LandMember2021-03-310001237831us-gaap:EquipmentMember2021-03-310001237831us-gaap:BuildingAndBuildingImprovementsMember2021-03-310001237831srt:OtherPropertyMember2021-03-310001237831gmed:ModulesAndCasesMember2021-03-310001237831gmed:InstrumentsMember2021-03-310001237831us-gaap:LandMember2020-12-310001237831us-gaap:EquipmentMember2020-12-310001237831us-gaap:BuildingAndBuildingImprovementsMember2020-12-310001237831srt:OtherPropertyMember2020-12-310001237831gmed:ModulesAndCasesMember2020-12-310001237831gmed:InstrumentsMember2020-12-310001237831gmed:StelkastAcquisitionMember2020-07-012020-09-300001237831us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001237831us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001237831us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001237831us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001237831us-gaap:LetterOfCreditMembergmed:CitizensBankMember2020-08-060001237831gmed:CitizensBankMember2020-08-060001237831gmed:CitizensBankMember2021-01-012021-03-310001237831gmed:CitizensBankMember2021-03-310001237831srt:MaximumMember2021-03-3100012378312020-01-012020-12-310001237831us-gaap:PatentsMember2021-01-012021-03-310001237831us-gaap:DevelopedTechnologyRightsMember2021-01-012021-03-310001237831us-gaap:CustomerRelationshipsMember2021-01-012021-03-310001237831gmed:SupplierNetworkMember2021-01-012021-03-310001237831us-gaap:PatentsMember2020-01-012020-12-310001237831us-gaap:DevelopedTechnologyRightsMember2020-01-012020-12-310001237831us-gaap:CustomerRelationshipsMember2020-01-012020-12-310001237831gmed:SupplierNetworkMember2020-01-012020-12-310001237831us-gaap:PatentsMember2021-03-310001237831us-gaap:DevelopedTechnologyRightsMember2021-03-310001237831us-gaap:CustomerRelationshipsMember2021-03-310001237831gmed:SupplierNetworkMember2021-03-310001237831us-gaap:PatentsMember2020-12-310001237831us-gaap:DevelopedTechnologyRightsMember2020-12-310001237831us-gaap:CustomerRelationshipsMember2020-12-310001237831gmed:SupplierNetworkMember2020-12-310001237831us-gaap:EmployeeStockOptionMember2021-03-310001237831gmed:CitizensBankMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-08-062020-08-060001237831us-gaap:FederalFundsEffectiveSwapRateMember2020-08-062020-08-060001237831us-gaap:RetainedEarningsMember2021-01-012021-03-310001237831us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001237831us-gaap:RetainedEarningsMember2020-01-012020-03-310001237831us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001237831us-gaap:CommonClassBMember2021-03-310001237831us-gaap:CommonClassAMember2021-03-310001237831us-gaap:CommonClassBMember2020-12-310001237831us-gaap:CommonClassAMember2020-12-3100012378312020-03-3100012378312019-12-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001237831us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001237831us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001237831gmed:SynosteAcquisitionMember2020-06-300001237831srt:WeightedAverageMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2021-03-310001237831srt:WeightedAverageMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputComparabilityAdjustmentMember2021-03-310001237831srt:WeightedAverageMemberus-gaap:FairValueInputsLevel3Membergmed:MeasurementInputProbabilityOfPaymentMember2021-03-310001237831srt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2021-03-310001237831srt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputComparabilityAdjustmentMember2021-03-310001237831srt:MinimumMemberus-gaap:FairValueInputsLevel3Membergmed:MeasurementInputProbabilityOfPaymentMember2021-03-310001237831srt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2021-03-310001237831srt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputComparabilityAdjustmentMember2021-03-310001237831srt:MaximumMemberus-gaap:FairValueInputsLevel3Membergmed:MeasurementInputProbabilityOfPaymentMember2021-03-310001237831us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001237831us-gaap:FairValueMeasurementsRecurringMember2021-03-310001237831us-gaap:FairValueInputsLevel3Member2021-03-310001237831us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001237831us-gaap:FairValueMeasurementsRecurringMember2020-12-310001237831us-gaap:FairValueInputsLevel3Member2020-12-310001237831gmed:TwoAcquisitionsMember2020-12-310001237831gmed:SynosteAcquisitionMembergmed:ThirdAnniversaryMember2020-06-300001237831gmed:SynosteAcquisitionMembergmed:FourthAnniversaryMember2020-06-300001237831us-gaap:FairValueInputsLevel3Member2020-03-310001237831us-gaap:FairValueInputsLevel3Member2019-12-310001237831gmed:StelkastAcquisitionMember2019-06-300001237831gmed:StelkastAcquisitionMember2019-04-012019-06-300001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-03-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2021-03-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-03-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-03-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2021-03-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-03-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2020-12-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001237831us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2020-12-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001237831us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310001237831us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-03-310001237831us-gaap:MunicipalBondsMemberus-gaap:OtherLongTermInvestmentsMember2021-03-310001237831us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-03-310001237831us-gaap:CorporateDebtSecuritiesMemberus-gaap:OtherLongTermInvestmentsMember2021-03-310001237831us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2021-03-310001237831us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-03-310001237831us-gaap:AssetBackedSecuritiesMemberus-gaap:OtherLongTermInvestmentsMember2021-03-310001237831gmed:MunicipalBondsShortTermMemberus-gaap:ShortTermInvestmentsMember2021-03-310001237831us-gaap:ShortTermInvestmentsMember2021-03-310001237831us-gaap:OtherLongTermInvestmentsMember2021-03-310001237831us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2020-12-310001237831us-gaap:MunicipalBondsMemberus-gaap:OtherLongTermInvestmentsMember2020-12-310001237831us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2020-12-310001237831us-gaap:CorporateDebtSecuritiesMemberus-gaap:OtherLongTermInvestmentsMember2020-12-310001237831us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2020-12-310001237831us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2020-12-310001237831us-gaap:AssetBackedSecuritiesMemberus-gaap:OtherLongTermInvestmentsMember2020-12-310001237831gmed:MunicipalBondsShortTermMemberus-gaap:ShortTermInvestmentsMember2020-12-310001237831us-gaap:ShortTermInvestmentsMember2020-12-310001237831us-gaap:OtherLongTermInvestmentsMember2020-12-310001237831us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001237831us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001237831us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001237831gmed:EquityIncentivePlan2012Member2021-03-310001237831srt:MaximumMembergmed:EquityIncentivePlan2012Member2021-03-310001237831srt:MinimumMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001237831srt:MaximumMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001237831us-gaap:CommonClassAMember2021-01-012021-03-310001237831gmed:CommonClassaAndBMember2021-01-012021-03-310001237831srt:MinimumMember2021-03-3100012378312020-01-012020-03-310001237831us-gaap:CommonClassBMember2021-01-012021-03-310001237831gmed:TwoAcquisitionsMember2020-10-012020-12-310001237831gmed:SynosteAcquisitionMember2020-04-012020-06-300001237831us-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001237831us-gaap:FairValueInputsLevel3Member2020-01-012020-03-310001237831srt:MinimumMemberus-gaap:OtherLongTermInvestmentsMember2021-01-012021-03-310001237831srt:MaximumMemberus-gaap:ShortTermInvestmentsMember2021-01-012021-03-310001237831srt:MaximumMemberus-gaap:OtherLongTermInvestmentsMember2021-01-012021-03-310001237831srt:MinimumMemberus-gaap:OtherLongTermInvestmentsMember2020-01-012020-12-310001237831srt:MaximumMemberus-gaap:ShortTermInvestmentsMember2020-01-012020-12-310001237831srt:MaximumMemberus-gaap:OtherLongTermInvestmentsMember2020-01-012020-12-3100012378312021-03-3100012378312020-12-3100012378312021-04-3000012378312021-01-012021-03-31gmed:segmentiso4217:USDxbrli:sharesgmed:ShareBasedCompensationPlangmed:itemxbrli:sharesgmed:itemxbrli:pureiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to _______________

Commission File No. 001-35621

GLOBUS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

04-3744954

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

2560 General Armistead Avenue, Audubon, PA 19403

 

(610) 930-1800

(Address of principal executive offices) (Zip Code)

 

(Registrant’s telephone number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of exchange on which registered

Class A Common Stock, par value $.001 per share

GMED

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes   No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files):

Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

Smaller Reporting Company

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes   No 

The number of shares outstanding of the issuer’s common stock (par value $0.001 per share) as of April 30, 2021 was 100,360,661 shares.

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements

 

 

Condensed Consolidated Balance Sheets (Unaudited)

 

 

March 31, 2021 and December 31, 2020

3

 

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

 

 

Three months ended March 31, 2021 and March 31, 2020

4

Condensed Consolidated Statements of Equity (Unaudited)

 

Three months ended March 31, 2021 and March 31, 2020

5

 

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

 

Three months ended March 31, 2021 and March 31, 2020

6

 

Notes to Condensed Consolidated Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

29

Item 4.

Controls and Procedures

29

PART II.

OTHER INFORMATION

31

Item 1.

Legal Proceedings

31

Item 1A.

Risk Factors

31

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

31

Item 3.

Defaults Upon Senior Securities

31

Item 4.

Mine Safety Disclosures

31

Item 5.

Other Information

31

Item 6.

Exhibits

31

 

SIGNATURES

33

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31,

December 31,

(In thousands, except share and per share values)

2021

2020

ASSETS

Current assets:

Cash, cash equivalents, and restricted cash

$

184,848

$

239,397

Short-term marketable securities

218,711

187,344

Accounts receivable, net of allowances of $4,358 and $4,408, respectively

160,939

141,676

Inventories

232,007

229,153

Prepaid expenses and other current assets

16,132

17,771

Income taxes receivable

1,736

6,424

Total current assets

814,373

821,765

Property and equipment, net of accumulated depreciation of $282,346 and $276,451, respectively

216,186

216,879

Long-term marketable securities

434,877

358,522

Intangible assets, net

80,414

86,949

Goodwill

155,373

156,716

Other assets

28,693

32,039

Deferred income taxes

7,974

6,615

Total assets

$

1,737,890

$

1,679,485

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable

$

22,409

$

18,205

Accrued expenses

69,908

78,334

Income taxes payable

8,434

1,101

Business acquisition liabilities

6,048

5,777

Deferred revenue

8,653

8,125

Payable to broker

8,225

9,250

Total current liabilities

123,677

120,792

Business acquisition liabilities, net of current portion

29,973

31,493

Deferred income taxes

5,925

6,202

Other liabilities

15,321

14,701

Total liabilities

174,896

173,188

Commitments and contingencies (Note 15)

 

 

Equity:

Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 77,587,013 and 77,284,007 shares at March 31, 2021 and December 31, 2020, respectively

78

77

Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 shares at March 31, 2021 and December 31, 2020

22

22

Additional paid-in capital

474,307

457,161

Accumulated other comprehensive income (loss)

(1,824)

3,955

Retained earnings

1,090,411

1,045,082

Total equity

1,562,994

1,506,297

Total liabilities and equity

$

1,737,890

$

1,679,485

See accompanying notes to unaudited condensed consolidated financial statements.


GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

Three Months Ended

March 31,

(In thousands, except per share amounts)

2021

2020

Net sales

$

227,344

$

190,577

Cost of goods sold

55,027

48,864

Gross profit

172,317

141,713

Operating expenses:

Research and development

14,924

15,402

Selling, general and administrative

97,891

93,539

Provision for litigation

(94)

Amortization of intangibles

4,774

3,776

Acquisition related costs

274

548

Total operating expenses

117,769

113,265

Operating income/(loss)

54,548

28,448

Other income/(expense), net

Interest income/(expense), net

2,712

4,324

Foreign currency transaction gain/(loss)

(280)

(468)

Other income/(expense)

214

194

Total other income/(expense), net

2,646

4,050

Income/(loss) before income taxes

57,194

32,498

Income tax provision

11,865

6,549

Net income/(loss)

$

45,329

$

25,949

Other comprehensive income/(loss):

Unrealized gain/(loss) on marketable securities, net of tax

(1,666)

(3,842)

Foreign currency translation gain/(loss)

(4,113)

474

Total other comprehensive income/(loss)

(5,779)

(3,368)

Comprehensive income/(loss)

$

39,550

$

22,581

Earnings per share:

Basic

$

0.45

$

0.26

Diluted

$

0.44

$

0.25

Weighted average shares outstanding:

Basic

99,866

99,635

Diluted

102,420

102,146

See accompanying notes to unaudited condensed consolidated financial statements.

 

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited)

Class A
Common Stock

Class B
Common Stock

Additional paid-in

Accumulated other comprehensive

Retained

(In thousands)

Shares

$

Shares

$

capital

income/(loss)

earnings

Total

Balance at December 31, 2020

77,284

$

77

22,430

$

22

$

457,161

$

3,955

$

1,045,082

$

1,506,297

Stock-based compensation

7,883

7,883

Grant of restricted stock units

163

163

Exercise of stock options

303

1

9,100

9,101

Comprehensive income/(loss)

(5,779)

45,329

39,550

Balance at March 31, 2021

77,587

$

78

22,430

$

22

$

474,307

$

(1,824)

$

1,090,411

$

1,562,994

Class A
Common Stock

Class B
Common Stock

Additional paid-in

Accumulated other comprehensive

Retained

(In thousands)

Shares

$

Shares

$

capital

income/(loss)

earnings

Total

Balance at December 31, 2019

77,394

$

77

22,431

$

22

$

357,320

$

(2,898)

$

1,047,931

$

1,402,452

Cumulative effects of adoption of accounting standards

(468)

(468)

Stock-based compensation

6,902

6,902

Exercise of stock options

190

1

5,762

5,763

Comprehensive income/(loss)

(3,368)

25,949

22,581

Repurchase and retirement of common stock

(1,920)

(2)

(73,862)

(73,864)

Balance at March 31, 2020

75,664

$

76

22,431

$

22

$

369,984

$

(6,266)

$

999,550

$

1,363,366

See accompanying notes to unaudited condensed consolidated financial statements.

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months Ended

March 31,

(In thousands)

2021

2020

Cash flows from operating activities:

Net income

$

45,329

$

25,949

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

17,157

14,568

Amortization of premium (discount) on marketable securities

520

20

Write-down of excess and obsolete inventories

1,550

679

Stock-based compensation expense

7,698

6,807

Allowance for doubtful accounts

80

756

Change in fair value of business acquisition liabilities

258

506

Change in deferred income taxes

(808)

(2,895)

(Gain)/loss on disposal of assets, net

103

207

(Increase)/decrease in:

Accounts receivable

(20,346)

14,131

Inventories

(3,997)

(12,108)

Prepaid expenses and other assets

4,516

(205)

Increase/(decrease) in:

Accounts payable

4,212

(283)

Accrued expenses and other liabilities

(4,783)

(13,702)

Income taxes payable/receivable

12,081

7,863

Net cash provided by operating activities

63,570

42,293

Cash flows from investing activities:

Purchases of marketable securities

(185,110)

(57,418)

Maturities of marketable securities

39,850

71,766

Sales of marketable securities

33,818

5,374

Purchases of property and equipment

(13,672)

(22,314)

Net cash used in investing activities

(125,114)

(2,592)

Cash flows from financing activities:

Payment of business acquisition related liabilities

(1,537)

(566)

Proceeds from exercise of stock options

9,101

5,763

Repurchase of common stock

(73,864)

Net cash provided by/used in financing activities

7,564

(68,667)

Effect of foreign exchange rates on cash

(569)

(16)

Net increase in cash, cash equivalents, and restricted cash

(54,549)

(28,982)

Cash, cash equivalents, and restricted cash at beginning of period

239,397

195,724

Cash, cash equivalents, and restricted cash at end of period

$

184,848

$

166,742

Supplemental disclosures of cash flow information:

Income taxes paid

$

570

$

1,791

Purchases of property and equipment included in accounts payable and accrued expenses

$

2,620

$

5,287

See accompanying notes to unaudited condensed consolidated financial statements.

6


Table of Contents

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

NOTE 1. BACKGROUND

(a) The Company

Globus Medical, Inc., together with its subsidiaries, is a medical device company that develops and commercializes healthcare solutions with a mission to improve the quality of life of patients with musculoskeletal disorders. We are primarily focused on implants that promote healing in patients with musculoskeletal disorders, including the use of a robotic guidance and navigation system and products to treat patients who have experienced orthopedic traumas.

We are an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures to assist surgeons in effectively treating their patients and to address new treatment options. With over 220 product launches to date, we offer a comprehensive portfolio of innovative and differentiated technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.

We are headquartered in Audubon, Pennsylvania, and we market and sell our products through our exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. Our sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.

The terms the “Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries.

(b) COVID-19 Pandemic Impact

In March 2020, the World Health Organization declared the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has significantly impacted the economic conditions in the U.S. and globally as federal, state and local governments react to the public health crisis, creating significant uncertainties in the economy.

Although the Company cannot reasonably estimate the length or severity of the impact that COVID-19 will have on its financial results, the Company may experience a material adverse impact on its sales, results of operations, and cash flows in 2021 should there be a resurgence impacting hospitals and surgical facilities to which we provide services.

In response to these developments, the Company will continue to monitor liquidity and cash flow. The Company has the ability to borrow from a credit facility signed in August 2020, if needed, although we do not expect to do so due to our cash, cash equivalents and short-term marketable securities balances.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Presentation

The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on February 17, 2021.

In the opinion of management, these condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position as of March 31, 2021, and results of operations for the three months ended March 31, 2021. The results of operations for any interim period may not be indicative of results for the full year.

(b) Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

7


Table of Contents

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

(c) Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary.

Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.

(d) Revenue Recognition

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. For purposes of disclosure, we disaggregate our revenue into two categories, Musculoskeletal Solutions and Enabling Technologies. Our Musculoskeletal Solutions products consist primarily of the implantable devices, disposables, and unique instruments used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of contracts with our customers for Musculoskeletal Solutions products have a single performance obligation and revenue is recognized at a point in time. Our Enabling Technologies products are advanced robotics hardware systems and related technologies that are designed to enhance a surgeon’s capabilities and streamline surgical procedures by making them less invasive, more accurate, and more reproducible to improve patient care. The majority of contracts with our customers for Enabling Technologies products contain multiple performance obligations, including maintenance and support, and revenue is recognized as we fulfill each performance obligation. When contracts have multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

Nature of Products and Services

A significant portion of our Musculoskeletal Solutions product revenue is generated from consigned inventory maintained at hospitals or with sales representatives. Revenue from the sale of consigned musculoskeletal products is recognized when we transfer control, which generally occurs at the time the product is used or implanted. For all other Musculoskeletal Solutions product transactions, we recognize revenue when we transfer title to the goods, provided there are no remaining performance obligations that can affect the customer’s final acceptance of the sale.

Revenue from the sale of Enabling Technologies products is generally recognized when control transfers to the customer which occurs at the time the product is shipped or delivered. Any revenue related to the provision of maintenance and support is recognized as we satisfy the performance obligation. We use an observable price to determine the stand-alone selling price for each separate performance obligation.

Contract Balances

Timing of revenue recognition may differ from the timing of invoicing to customers. We record a receivable when revenue is recognized prior to invoicing, or deferred revenue when revenue is recognized subsequent to invoicing.

Deferred revenue is comprised mainly of unearned revenue related to the sales of certain Enabling Technologies products, which includes maintenance and support services. Maintenance and support services are generally invoiced annually, at the beginning of each contract period, and revenue is recognized ratably over the maintenance period. For the three months ended March 31, 2021 and 2020, there was an immaterial amount of revenue recognized from previously deferred revenue.

8


Table of Contents

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

(e) Cash, Cash Equivalents, and Restricted Cash

The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, commercial paper and corporate debt securities are stated at fair value.

(f) Marketable Securities

Our marketable securities include municipal bonds, corporate debt securities, commercial paper, asset-backed securities, and securities of government, federal agency, and other sovereign obligations are classified as available-for-sale as of March 31, 2021 and December 31, 2020. Short-term and long-term marketable securities are recorded at fair value on our condensed consolidated balance sheets. Any changes in the fair value of our available-for-sale securities, that do not result in recognition or reversal of an allowance for credit loss or write-down, are recorded, net of taxes, as a component of accumulated other comprehensive income or loss on our condensed consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of marketable securities are determined on a specific identification basis. Realized gains and losses, interest income and the amortization/accretion of premiums/discounts are included in other income/(expense), net, on our condensed consolidated statements of operations and comprehensive income. Interest receivable is recorded in prepaid expenses and other current assets on our condensed consolidated balance sheets.

We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is expected, the loss will be recognized on an allowance basis, consistent with ASC 326-30, in our condensed consolidated statement of operations and comprehensive income in the period the determination is made.

(g) Fair Value Measurements

Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis

Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and

Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.

Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis

The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value.

9


Table of Contents

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to business acquisitions and is measured at fair value, based on significant inputs that are not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these assumptions on an ongoing basis as additional data impacting the assumptions is obtained. The fair value of contingent consideration recorded in business acquisition liabilities on our condensed consolidated balance sheets, and changes in the fair value of contingent consideration are recognized within acquisition related costs in the condensed consolidated statements of operations and comprehensive income. The fair value of contingent restricted stock unit (“RSU”) grants are recorded as additional paid-in capital in the consolidated balance sheet on the day of the grant due to the remote likelihood of forfeiture.

(h) Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The majority of our inventory is finished goods and we utilize both in-house manufacturing and third-party suppliers to produce our products. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a write-down for such excess inventories. Once inventory has been written down, it creates a new cost basis for inventory that is not subsequently written up.

(i) Goodwill and Intangible Assets

Goodwill represents the excess of purchase price over the fair values of the identifiable assets acquired less the liabilities assumed in the acquisition of a business. Goodwill is tested for impairment at least annually or whenever events or circumstances indicate that a carrying amount may not be recoverable. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. Fair values are estimated using an income and discounted cash flow approach. We perform our annual impairment test of goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. During the three months ended March 31, 2021 and 2020, we did not record any impairment charges related to goodwill.

Intangible assets consist of purchased in-process research and development (“IPR&D”), developed technology, supplier network, patents, customer relationships, re-acquired rights, and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to sixteen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If an impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis. There were no impairments of finite-lived intangible assets during the three months ended March 31, 2021 or 2020.

IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. There were no impairments of IPR&D during the three months ended March 31, 2021 or 2020.

(j) Stock-Based Compensation

The cost of employee and non-employee director awards is measured at the grant date fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the equity award. Compensation expense for awards includes the impact of forfeiture in the period when they occur.

We estimate the fair value of stock options utilizing the Black-Scholes option-pricing model. Inputs to the Black-Scholes model include our stock price, expected volatility, expected term, risk-free interest rate and expected dividends. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts. The fair value of restricted stock units is estimated using the closing price of the Company’s common stock on the date of grant.

10


Table of Contents

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

(k) Recently Issued Accounting Pronouncements

On March 12, 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is effective for all entities as of March 12, 2020, and will apply through December 31, 2022. To date, we have had no impacts on our investment portfolio or our credit agreement with Citizens Bank, N.A. related to reference rate reform. We will continue to evaluate the impact this guidance could have on our condensed consolidated financial statements and related disclosures.

(l) Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. We adopted ASU 2019-12 on January 1, 2021. This standard did not have a material impact on our financial position, results of operations and disclosures. 

NOTE 3. ASSET ACQUISITIONS AND BUSINESS COMBINATIONS

Asset Acquisitions

During the second quarter of 2020, the Company acquired Synoste Oy (“Synoste”), a Finnish engineering company that specializes in the research and development of a limb lengthening system. The fair value of the net assets acquired was $25.3 million, and the consideration consisted of approximately $22.8 million of cash paid at closing plus $2.5 million of a contractual holdback obligation payable eighteen months from the closing date of the transaction, subject to net working capital and other post-closing adjustments, if applicable. The contractual holdback obligation is included in accrued expenses in the condensed consolidated balance sheet.

The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset, IPR&D of the limb lengthening system, thus satisfying the requirements of the screen test in ASU 2017-1. At the date of acquisition, the Company determined that the development of the projects underway at Synoste had not yet reached technological feasibility and that the research in process had no alternative future use. Accordingly, the acquired IPR&D of $24.4 million was charged to research and development expense in the condensed consolidated statements of operations and comprehensive income at the date of acquisition.

The transaction also provides for additional consideration contingent upon the developed product obtaining approval from the U.S. Food and Drug Administration (the “FDA”) of $8.0 million within the third anniversary, or $4.0 million within the fourth anniversary of the acquisition closing date, respectively. Contingent consideration is not recorded in an asset acquisition until the milestone is met.

Business Combinations

During the fourth quarter of 2020, the Company completed two acquisitions that were not considered material, individually or collectively, to the condensed consolidated financial statements during the periods presented. These acquisitions have been included in the condensed consolidated financial statements from the date of acquisition. The combined purchase price consisted of approximately $1.5 million of cash paid at closing, plus $0.3 million of other liabilities and $33.2 million of contingent consideration payments. The contingent payments are based upon achieving various performance obligations over a period of 10 years, and are payable in a combination of cash and RSUs. The Company recorded other intangible assets of $8.8 million, with a weighted average useful life of 4.2 years, and goodwill of $26.2 million based on their preliminary estimated fair values. The purchase price allocation of the assets and liabilities acquired remains open with respect to the final determination of deferred tax asset values. The Company expects the purchase price allocation to be finalized within one year from the date of acquisition. While the Company does not expect material changes from the initial outcome of the valuation, certain assumptions and findings made at the date of acquisition could result in changes in the purchase price allocation.

11


Table of Contents

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

During the second quarter of 2019, the Company acquired substantially all of the assets of StelKast, Inc. (the “StelKast Acquisition”), a privately held company that designs, manufactures and distributes orthopedic implants for knee and hip replacement surgeries. The Company has included the financial results from the StelKast Acquisition in our condensed consolidated financial statements from the acquisition date. At the acquisition date, the fair value of the net assets acquired was $28.1 million. The purchase price consisted of approximately $23.8 million of cash paid at closing, plus $4.3 million of contingent consideration payable based upon the achievement of product sales milestones. The Company recorded identifiable net assets, based on their estimated fair values, for inventory of $15.3 million, fixed assets of $4.2 million and customer relationships of $3.9 million and goodwill of $4.7 million.

The contingent consideration payable related to the StelKast Acquisition of $5.0 million was paid during the third quarter of 2020.

NOTE 4. NET SALES

The following table represents net sales by product category:

Three Months Ended

March 31,

(In thousands)

2021

2020

Musculoskeletal Solutions

$

212,416

$

182,542

Enabling Technologies

14,928

8,035

Total net sales

$

227,344

$

190,577

NOTE 5. MARKETABLE SECURITIES

The composition of our short-term and long-term marketable securities was as follows:

March 31, 2021

(In thousands)

Amortized
Cost

Gross
Unrealized
Gains

Gross Unrealized Losses

Fair
Value

Short-term:

Municipal bonds

$

60,961

$

262

$

(1)

$

61,222

Corporate debt securities

112,231

1,220

(1)

113,450

Commercial paper

30,556

7

30,563

Asset-backed securities

5,560

6

5,566

Government, federal agency, and other sovereign obligations

7,880

30

7,910

Total short-term marketable securities

$

217,188

$

1,525

$

(2)

$

218,711

Long-term:

Municipal bonds

$

69,833

$

331

$

(29)

$

70,135

Corporate debt securities

213,444

1,646

(170)

214,920

Asset-backed securities

148,761

1,158

(97)

149,822

Total long-term marketable securities

$

432,038

$

3,135

$